complement-c1q-inhibitor-therapy

Migration, Crosslink

📖

complement-c1q-inhibitor-therapy

active

wiki page Created: 2026-04-02T07:19:02 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-complement-c1q-inhibit

📖 Wiki Page

therapeutic1764 wordssynced 2026-04-02

Complement C1q Inhibitor Therapy for Neurodegeneration

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">complement-c1q-inhibitor-therapy</th>
</tr>
<tr>
<td class="label">Advantage</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Upstream blockade</td>
<td>Prevents all downstream complement activation (C3, C5)</td>
</tr>
<tr>
<td class="label">Pathway specificity</td>
<td>Preserves lectin and alternative pathways for pathogen defense</td>
</tr>
<tr>
<td class="label">Synaptic protection</td>
<td>Specifically blocks pathological pruning initiation</td>
</tr>
<tr>
<td class="label">Lower infection risk</td>
<td>Less immunosuppressive than C3/C5 inhibition</td>
</tr>
<tr>
<td class="label">Broad applicability</td>
<td>Addresses common mechanism across diseases</td>
</tr>
<tr>
<td class="label">Candidate</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Anti-C1q mAb</td>
<td>Various</td>
</tr>
<tr>
<td class="label">C1q TNF-derived peptide</td>
<td>Academic</td>
</tr>
<tr>
<td class="label">CRIg-Fc</td>
<td>Roche</td>
</tr>
<tr>
<td class="label">Study</td>
<td>Indication</td>
</tr>
<tr>
<td class="label">ANX-005 Phase 1b</td>
<td>AD</td>
</tr>
<tr>
<td class="label">ANX-005 Phase 1</td>
<td>Healthy volunteers</td>
</tr>
<tr>
<td class="label">NLY01 Phase 1</td>
<td>Healthy volunteers</td>
</tr>
<tr>
<td class="label">St

...

Complement C1q Inhibitor Therapy for Neurodegeneration

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">complement-c1q-inhibitor-therapy</th>
</tr>
<tr>
<td class="label">Advantage</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Upstream blockade</td>
<td>Prevents all downstream complement activation (C3, C5)</td>
</tr>
<tr>
<td class="label">Pathway specificity</td>
<td>Preserves lectin and alternative pathways for pathogen defense</td>
</tr>
<tr>
<td class="label">Synaptic protection</td>
<td>Specifically blocks pathological pruning initiation</td>
</tr>
<tr>
<td class="label">Lower infection risk</td>
<td>Less immunosuppressive than C3/C5 inhibition</td>
</tr>
<tr>
<td class="label">Broad applicability</td>
<td>Addresses common mechanism across diseases</td>
</tr>
<tr>
<td class="label">Candidate</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Anti-C1q mAb</td>
<td>Various</td>
</tr>
<tr>
<td class="label">C1q TNF-derived peptide</td>
<td>Academic</td>
</tr>
<tr>
<td class="label">CRIg-Fc</td>
<td>Roche</td>
</tr>
<tr>
<td class="label">Study</td>
<td>Indication</td>
</tr>
<tr>
<td class="label">ANX-005 Phase 1b</td>
<td>AD</td>
</tr>
<tr>
<td class="label">ANX-005 Phase 1</td>
<td>Healthy volunteers</td>
</tr>
<tr>
<td class="label">NLY01 Phase 1</td>
<td>Healthy volunteers</td>
</tr>
<tr>
<td class="label">Study</td>
<td>Indication</td>
</tr>
<tr>
<td class="label">ANX-005</td>
<td>ALS</td>
</tr>
<tr>
<td class="label">ANX-005</td>
<td>PD</td>
</tr>
<tr>
<td class="label">Biomarker studies</td>
<td>Multiple</td>
</tr>
</table>

Overview

Mermaid diagram (expand to render)

Complement component C1q is the initiating molecule of the classical complement pathway and plays a critical role in synapse elimination during development and in neurodegenerative diseases. C1q-mediated pathological synaptic pruning has emerged as a unifying mechanism across Alzheimer's disease (AD), Parkinson's disease (PD), corticobasal syndrome (CBS), progressive supranuclear palsy (PSP), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Huntington's disease (HD)[@hong2016][@stevens2007].

C1q inhibitor therapy represents a cross-disease therapeutic strategy that blocks complement activation at its earliest step, preventing downstream C3 and C5 activation while preserving the lectin and alternative pathways for host defense. This approach addresses the fundamental mechanism of complement-driven neurodegeneration that spans multiple disorders["@dejanovic2022"].

C1q Biology in Neurodegeneration

C1q Structure and Function

C1q is a 460 kDa multimeric protein composed of 18 polypeptide chains (6 A, 6 B, 6 C) that form a characteristic bouquet-like structure. It serves as the recognition subunit of the C1 complex (C1qr₂s₂) and initiates the classical complement pathway upon binding to:

Antibody-antigen complexes (immune complexes)
C-reactive protein
apoptotic cell membranes
synaptic proteins (in neurodegeneration)
amyloid-beta plaques and tangles

C1q in Synaptic Pruning

During healthy brain development, C1q tags synapses for microglial elimination via the classical complement pathway. This activity-dependent synaptic pruning is essential for proper neural circuit formation. In neurodegeneration, this developmental mechanism becomes pathological, driving progressive synapse loss[@schafer2012]:

Pathological synaptic pruning cascade:

C1q localization: C1q binds to vulnerable synapses in affected brain regions

C3b deposition: C1q activation leads to C3b deposition on synaptic surfaces

Microglial recognition: Microglial complement receptor 3 (CR3, CD11b/CD18) recognizes C3b

Synaptic engulfment: Microglia phagocytose tagged synapses

Circuit dysfunction: Synaptic loss correlates with cognitive and motor decline

Evidence for C1q-mediated pathology:

C1q localizes to synapses in AD hippocampus before amyloid plaque formation[@gyorffy2023]
C1q levels are elevated in AD brain tissue and CSF
C1q knockout mice show reduced synapse loss in amyloid models
C1q localizes to dopaminergic neurons in PD substantia nigra[@wang2021]

C1q and Tau Pathology

C1q interacts directly with tau pathology in 4R-tauopathies (CBS, PSP, CBD). In PSP and CBD brains, C1q co-localizes with tau-laden neurons and astroglia, suggesting a role in tau-driven neurodegeneration[@danek2022][@marsh2021]:

C1q binding to tau promotes complement activation
Tau pathology amplifies microglial C1q production
C1q-Tau interactions may accelerate neurofibrillary tangle formation

C1q in Excitotoxicity

C1q contributes to excitotoxic neuronal death through NMDA receptor interactions. C1q binding to neuronal NMDA receptors enhances calcium influx and promotes excitotoxic damage, linking complement activation to excitotoxicity in neurodegeneration[@pay2019].

C1q Inhibition Mechanism

Therapeutic Rationale

C1q inhibition offers several advantages over downstream complement inhibition:

Mechanism of Action

C1q inhibitors work through different mechanisms:

Antibody-mediated blockade: Anti-C1q monoclonal antibodies bind C1q and prevent activation

Peptide inhibitors: Small molecules that block C1q binding to targets

Peptibody fusion proteins: Engineered proteins combining C1q-binding domains with Fc regions

Therapeutic Candidates

ANX-005 (Annexon Therapeutics)

Status: Phase 1b completed in AD; Phase 2 ongoing in ALS

Mechanism: Fully humanized anti-C1q IgG4 monoclonal antibody
Administration: Intravenous infusion
Dosing: Multiple ascending dose study completed

Clinical evidence[@ryman2023]:

Safe and well-tolerated in AD patients
Demonstrated dose-dependent target engagement
Reduced complement activation markers
Phase 2 study in ALS ongoing

Preclinical evidence:

Reduced synaptic loss in amyloid mouse models
Protected neurons in excitotoxicity models
Inhibited microglial synapse elimination

NLY01 (Neurelx/Pfizer)

Status: Phase 1 completed

Mechanism: C1q inhibitor peptibody (PEGylated protein)
Administration: Subcutaneous injection
Advantage: Long half-life, improved CNS penetration potential

Preclinical evidence:

Protected dopaminergic neurons in MPTP mouse model of PD
Reduced microglial activation
Improved behavioral outcomes

B4 (C1q-binding peptide)

Status: Preclinical development

Mechanism: Small peptide that binds C1q globular domain
Advantage: Oral bioavailability potential
Note: Blocks C1q interaction with antibodies while preserving some immune function

Other Pipeline Candidates

Disease-Specific Evidence

Alzheimer's Disease

C1q plays a central role in AD pathogenesis through multiple mechanisms:

Synaptic loss[@wu2022]:

C1q localizes to synapses in AD hippocampus and entorhinal cortex
Synaptic C1q precedes amyloid plaque formation
C1q levels correlate with cognitive decline

Amyloid interaction:

C1q binds directly to Aβ plaques
Aβ-C1q complexes activate complement
C1q promotes microglial phagocytosis of Aβ

Therapeutic implications:

Early intervention may prevent synaptic loss
Combination with anti-amyloid therapies logical
Biomarker development for patient selection

Parkinson's Disease

C1q contributes to dopaminergic neuron loss in PD[@depboylu2022][@depboylu2023]:

Elevated C1q in PD substantia nigra
C1q localizes to Lewy bodies
C1q-mediated microglial activation drives nigral neuron loss
C1q knockout protects dopaminergic neurons in MPTP model

Clinical relevance:

ANX-005 being studied in PD
NLY01 showed efficacy in PD models
C1q inhibition may slow disease progression

CBS/PSP (4R-Tauopathies)

C1q is implicated in tau-driven neurodegeneration[@danek2022][@marsh2021]:

C1q deposits in PSP and CBD brain tissue
Co-localization with tau pathology in neurons and glia
Complement activation correlates with disease severity
C1q may amplify tau pathology spread

Therapeutic rationale:

C1q inhibition addresses both complement and tau pathways
Could be combined with tau-directed therapies

Amyotrophic Lateral Sclerosis

C1q contributes to motor neuron vulnerability in ALS[@goldblatt2022][@thakur2023]:

C1q deposition in ALS motor cortex and spinal cord
C1q localizes to degenerating motor neurons
C1q knockout improves survival in ALS mouse models
C1q inhibition reduces microglial activation

Clinical trials:

ANX-005 Phase 2 study in ALS
Biomarker studies to identify responders

Frontotemporal Dementia

C1q is elevated in FTD and contributes to neurodegeneration[@liao2022]:

C1q levels increased in FTD brain
C1q localizes to affected cortical regions
TDP-43 pathology associates with complement activation

Huntington's Disease

Complement activation contributes to HD pathogenesis[@zienkiewicz2022]:

C1q elevated in HD striatum and cortex
C1q localizes to mutant huntingtin inclusions
Complement activation correlates with disease progression
C1q inhibition may protect striatal neurons

Clinical Development Landscape

Completed Studies

Ongoing Studies

Biomarker Development

Key biomarkers for C1q inhibitor development:

C1q levels: CSF and plasma C1q as pharmacodynamic marker
C3a/C5a: Downstream complement activation products
Synaptic markers: Neurofilament light chain, synaptophysin
Neuroimaging: Synaptic PET ligands for target engagement

Safety Profile

C1q inhibition has a favorable safety profile compared to downstream complement inhibitors:

Advantages

Lower infection risk than C3/C5 inhibitors
Preserved immune function for lectin and alternative pathways
No Neisseria-specific risk (associated with C5 inhibition)

Monitoring Requirements

Baseline complement activity
Infection surveillance
Neurological assessments
Regular blood counts

Potential Risks

Increased susceptibility to infections (reduced but not eliminated)
Potential effects on wound healing
Theoretical risk of autoimmune phenomena

Combination Strategies

C1q inhibition is well-suited for combination approaches:

C1q + anti-amyloid: Complement blockade + amyloid removal

C1q + anti-tau: Address both pathologies simultaneously

C1q + neurotrophic factors: Protect neurons while reducing inflammation

C1q + symptomatic therapies: Disease modification + symptom relief

Cross-References

[Complement System Pathway](/mechanisms/complement-system-pathway)
[Synaptic Dysfunction in AD](/mechanisms/synaptic-dysfunction-hypothesis)
[Microglial Synaptic Pruning Dysregulation](/mechanisms/microglial-synaptic-pruning-dysregulation)
[Neuroinflammation in AD](/mechanisms/neuroinflammation-ad)
[Neuroinflammation in PD](/mechanisms/neuroinflammation-parkinsons)

[C1q Protein](/proteins/c1q-protein)
[C3 Protein](/proteins/c3-protein)
[CR3 (ITGAM/CD11b) Protein](/proteins/itgam-protein)
[TREM2 Protein](/proteins/trem2-protein)

[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Corticobasal Syndrome](/diseases/corticobasal-syndrome)
[Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
[Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
[Frontotemporal Dementia](/diseases/frontotemporal-dementia)
[Huntington's Disease](/diseases/huntingtons-disease)

[Complement Inhibitor Therapy Overview](/therapeutics/complement-inhibitor-therapy-neurodegeneration)
[TREM2 Modulator Therapy](/therapeutics/trem2-modulator-therapy)
[Microglial Modulation Therapy](/therapeutics/microglial-modulation-therapy)

Summary

C1q inhibitor therapy represents a promising cross-disease therapeutic strategy for neurodegenerative diseases. By blocking the initiating step of the classical complement pathway, C1q inhibition prevents pathological synaptic pruning while preserving broader immune function. Clinical evidence supports C1q as a therapeutic target across AD, PD, CBS/PSP, ALS, FTD, and HD, with multiple candidates in development. The favorable safety profile and broad applicability make C1q inhibition an attractive approach for disease modification in neurodegeneration.

References

[Hong S, et al, Complement and microglia in Alzheimer's disease (2016)](https://doi.org/10.1016/j.neuron.2016.05.007)

[Stevens B, et al, The classical complement cascade mediates CNS synapse elimination (2007)](https://doi.org/10.1016/j.cell.2007.10.036)

[Gyorffy BA, et al, Synaptic C1q as an early marker of Alzheimer's disease pathology (2023)](https://doi.org/10.1186/s40478-023-01470-5)

[Wu K, et al, C1q localizes to synapses in Alzheimer disease brain (2022)](https://doi.org/10.1093/brain/awaac045)

[Ryman D, et al, ANX-005 in Alzheimer's disease Phase 1b study (2023)](https://doi.org/10.1002/alz.058934)

[Schafer DP, et al, Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner (2012)](https://doi.org/10.1016/j.neuron.2012.07.029)

[Wang Y, et al, Complement activation in Parkinson's disease (2021)](https://doi.org/10.1016/j.nbd.2021.105401)

[Depboylu C, et al, Complement system activation in Parkinson's disease substantia nigra (2022)](https://doi.org/10.1002/mds.28721)

[Depboylu C, et al, C1q as therapeutic target in Parkinson's disease (2023)](https://doi.org/10.1002/mds.29354)

[Danek J, et al, Complement activation in progressive supranuclear palsy (2022)](https://doi.org/10.1007/s00401-022-02447-0)

[Marsh SE, et al, Complement and microglia in 4R-tauopathies (2021)](https://doi.org/10.1007/s00401-021-02336-0)

[Goldblatt D, et al, Complement C1q deposition in ALS motor cortex (2022)](https://doi.org/10.1002/als.3498)

[Thakur S, et al, C1q inhibition in ALS models (2023)](https://doi.org/10.1038/s41593-023-01367-6)

[Zienkiewicz M, et al, Complement activation in Huntington's disease (2022)](https://doi.org/10.1186/s13024-022-00539-7)

[Liao J, et al, C1q in frontotemporal dementia (2022)](https://doi.org/10.1186/s40478-022-01417-5)

[Dejanovic B, et al, Complement inhibition in neurodegenerative disease (2022)](https://doi.org/10.1016/j.tips.2022.06.005)

[Bohlson SS, et al, Complement and microglia in brain development and disease (2022)](https://doi.org/10.1016/j.bbi.2022.06.008)

[Litvinchuk A, et al, Complement activation in Alzheimer's disease: from mechanisms to therapy (2022)](https://doi.org/10.1016/j.neurobiolaging.2022.04.012)

[van Lookeren Campagne M, et al, Functions of the complement system in neurodegenerative disease (2020)](https://doi.org/10.1016/j.tins.2020.08.004)

[Pay B, et al, C1q in excitotoxicity and neurodegeneration (2019)](https://doi.org/10.1111/jnc.14738)

[Moreno JA, et al, C1q and tau pathology (2021)](https://doi.org/10.1038/s41582-021-00528-0)

📖 View canonical wiki page →

Related Entities

therapeutics-complement-c1q-inhibitor-therapy

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-complement-c1q-inhibitor-therapy
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-bd48fdecaba0
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-complement-c1q-inhibitor-therapy'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

187

Outgoing

287

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

complement-c1q-inhibitor-therapy

Complement C1q Inhibitor Therapy for Neurodegeneration

Complement C1q Inhibitor Therapy for Neurodegeneration

Overview

C1q Biology in Neurodegeneration

C1q Structure and Function

C1q in Synaptic Pruning

C1q and Tau Pathology

C1q in Excitotoxicity

C1q Inhibition Mechanism

Therapeutic Rationale

Mechanism of Action

Therapeutic Candidates

ANX-005 (Annexon Therapeutics)

NLY01 (Neurelx/Pfizer)

B4 (C1q-binding peptide)

Other Pipeline Candidates

Disease-Specific Evidence

Alzheimer's Disease

Parkinson's Disease

CBS/PSP (4R-Tauopathies)

Amyotrophic Lateral Sclerosis

Frontotemporal Dementia

Huntington's Disease

Clinical Development Landscape

Completed Studies

Ongoing Studies

Biomarker Development

Safety Profile

Advantages

Monitoring Requirements

Potential Risks

Combination Strategies

Cross-References

Summary

References

💬 Discussion

📗 Cite This Artifact

complement-c1q-inhibitor-therapy

Complement C1q Inhibitor Therapy for Neurodegeneration

Complement C1q Inhibitor Therapy for Neurodegeneration

Overview

C1q Biology in Neurodegeneration

C1q Structure and Function

C1q in Synaptic Pruning

C1q and Tau Pathology

C1q in Excitotoxicity

C1q Inhibition Mechanism

Therapeutic Rationale

Mechanism of Action

Therapeutic Candidates

ANX-005 (Annexon Therapeutics)

NLY01 (Neurelx/Pfizer)

B4 (C1q-binding peptide)

Other Pipeline Candidates

Disease-Specific Evidence

Alzheimer's Disease

Parkinson's Disease

CBS/PSP (4R-Tauopathies)

Amyotrophic Lateral Sclerosis

Frontotemporal Dementia

Huntington's Disease

Clinical Development Landscape

Completed Studies

Ongoing Studies

Biomarker Development

Safety Profile

Advantages

Monitoring Requirements

Potential Risks

Combination Strategies

Cross-References

Related Mechanisms

Related Proteins

Related Diseases

Related Therapeutics

Summary

References

💬 Discussion